Syndax initiated with a Buy at Mizuho

Mizuho analyst Mara Goldstein initiated coverage of Syndax Pharmaceuticals with a Buy rating and $45 price target. The shares have reset into 2024 following the American Society of Hematology meeting and a capital raise, the analyst tells investors in a research note. The firm views Syndax’s current valuation as an attractive entry point heading into regulatory filings and potential approvals. The company’s two near-term commercial opportunities bring upside drivers, contends Mizuho.